Navigation Links
Pulmo BioTech Inc. Announces Fund Raising Agreement with Moody Capital Solutions, Inc.
Date:6/15/2009

NEW YORK, June 15 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. (OTC Bulletin Board: PLMO; Frankfort Borse: PBO) has announced that it has entered into an exclusive agreement with Moody Capital Solutions, Inc. to secure up to $7.5 million in funding to enable the company to complete Phase II/III Approvals for its Pulmonary Hypertension (PH) diagnostic product candidate PulmoBind(TM).

"We are very pleased to be working with Moody Capital Solutions to raise the funding needed for our PH related Phase II/III Trials. Moody Capital Solutions, Inc. doing business as RedChip Securities, Inc. has an excellent reputation for pharma related fund raising and has substantial expertise in this area. By working with RedChip, we believe that we will be able to secure the funding to immediately start our Phase II/III work on successful completion of our Phase I Trials." - Garry McCann, CEO Pulmo BioTech Inc.

About Pulmo BioTech Inc.

Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Our mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stockholders.

ISIN: US7458451074

CUSIP: 745845107

About PulmoScience Inc.

PulmoScience Inc. was established in 2006, and is currently developing a non-invasive Molecular Imaging technique for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the trade name PulmoBind.

PulmoScience was conceived within the Montreal Heart Institute "MHI" (a world renowned hospital and educational facility). Jointly owned by MHI subsidiary Innovacor as the technical and operational partner, Dr. Jocelyn Dupuis (the scientific director and originator of the PulmoBind Molecular Imaging technology), and by Pulmo BioTech Inc. as the funding partner, PulmoScience Inc. aims to develop this unique and exciting technology, to fund necessary trials, and to bring the products to market.

PulmoScience believes that the market for its product candidates is worth in excess of $500 million per annum and that, provided Regulatory Approval is achieved, the safety and efficacy of its products could allow it to dominate that market.

About PulmoBind

PulmoBind uses an intravenously delivered radionuclide tagged molecule which specifically bonds to the inner walls of the circulatory system in the lungs, and by the use of an external Gamma Camera allows an image of the integrity of the blood vessels throughout the lungs to be seen by a diagnostic clinician. PulmoScience is currently undertaking Regulatory Approval for Phase I Human Trials, and while subsequent results from additional tests might not corroborate the current results, PulmoScience believes that PulmoBind has the potential to dominate the market for the diagnosis of Pulmonary Embolism. In particular, this belief is driven by PulmoScience's expectations of the improved safety and efficacy that PulmoBind will offer when compared to the current incumbent nuclear medicine based technology for the diagnosis of Pulmonary Embolism. In addition, early indications are that PulmoBind could be highly effective in the early stage diagnosis of Pulmonary Hypertension, a condition for which there is no current front line diagnostic test. The addressable market for the product candidates being developed by PulmoScience is believed by the company to be worth in excess of $500 million per annum.

Further Information

For further information regarding Pulmo BioTech Inc. or PulmoScience, please visit www.pulmobiotech.com

Forward-Looking Statements

Forward-looking statements contained in this and other written and oral reports are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. All statements regarding future performance, earnings projections, regulatory approval, events or developments are forward-looking statements. It is possible that the future performance of the company may differ materially from current expectations, depending on economic conditions and the uncertainty of regulatory approval. A change in economic conditions may have a particularly volatile effect on results. Among the other factors which may affect future performance are: competitive market conditions and resulting effects on sales and pricing; increases in raw-material costs that cannot be recovered in product pricing; and global economic factors, including difficulties entering new markets and general economic conditions such as inflation, interest rates and credit availability. The company makes these statements as of the date of this disclosure, and undertakes no obligation to update them.


'/>"/>
SOURCE Pulmo BioTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NYC-area 1st: Morgan Stanley Childrens Hospital performs transcatheter pulmonary valve replacement
2. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
3. Nuclear medicine approach can be first choice for excluding pulmonary embolism in young women
4. Resolution Recognizing Pulmonary Fibrosis Challenges Overwhelmingly Passes House
5. Deep Breeze Ltd. Launches Unique Non-Invasive, Radiation-Free Pulmonary Imaging System in the U.S.
6. Coalition for Pulmonary Fibrosis Fundraising Events Raise $280,000 for IPF
7. Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
8. A new method allows for the early diagnosis of pulmonary hypertension
9. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
10. Free Program Dec. 1 to Help Patients With Debilitating Pulmonary Disorder Alpha-1
11. Evel Knievel Lost to Pulmonary Fibrosis; Disease Claims as Many Lives as Breast Cancer Each Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Atlanta, Georgia (PRWEB) , ... May 26, 2016 ... ... a certificate in intellectual property (IP) to its specialty academic programs. , Answering ... joins the college’s existing certificate programs in health law, and environmental and land ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at John Knox ... new model of care for living and healing, celebrated its grand opening, today. The ... a Real Home provided by Empowered Staff. , “This is an incredibly fulfilling time ...
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line of ... New Hampshire at the MadgeTech headquarters. With products sold in more than 100 countries ... agencies, including NASA. , In 2012, NASA strategically set up 17 RHTemp101A ...
(Date:5/26/2016)... SURPRISE, ARIZ. (PRWEB) , ... May 26, 2016 , ... ... worry of American families. , The 550 employees of Sun Health Senior Living ... plan through Aetna that reduces their doctor and prescription copays for the year, while ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... supply chain solutions, today announced the organization has earned its ISO 13485 certification, ... and is compliant with all rules and policies associated with ISO quality standard ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016   ... endpoints demonstrating non-inferiority in overall bowel cleansing and superiority ... c leansing of the ... http://photos.prnewswire.com/prnh/20130829/633895-a ) , Norgine B.V. today announced new ... litre PEG and ascorbate bowel preparation) versus standard 2 litre PEG ...
(Date:5/24/2016)... -- Joe Marziani has joined VMS BioMarketing as senior vice president of sales, announced ... role, Marziani will lead the company,s business development and sales team, exploring new opportunities ... Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
(Date:5/24/2016)... Dutch surgeons have launched a ground-breaking medical ... and treat patients on a global scale. Medical professionals from ... Asia and the US have already signed up for ... in a totally secure environment. Education  "Imagine ... together with a surgeon at Harvard to treat a bomb victim ...
Breaking Medicine Technology: